FDA Clearance Tracker · P240040
Oncomine Dx Express Test
Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jul 2, 2025
Approved
Time to decision
232 days
Received Nov 12, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P240040
- Device name
- Oncomine Dx Express Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Frederick, MD
- Received
- Nov 12, 2024
- Decided
- Jul 2, 2025
- Decision
- Approved
- Supplements
- 6 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Oncomine Dx Express Test. The test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology to detect substitutions, insertions, and deletions in 42 genes from DNA, copy number variants (CNVs) in 10 genes from DNA, and fusions or splice variants in 18 genes from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor samples, using the Genexus Dx Integrated Sequencer. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling (see approval order for Table 1).Additionally, the test is intended to provide tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
K241806 · Decided Jan 8, 2025 · 201 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.